Author:
Syed Ali,Durham Lucian,Melamed Joshua,Pearson Paul J
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Left ventricular assist devices: a primer for the general cardiologist;Chaudhry SP;J Am Heart Assoc,2022
2. Assessment of an extracorporeal life support to LVAD bridge to heart transplant strategy;Pagani FD;Ann Thorac Surg,2000
3. The effectiveness and safety of the Impella ventricular assist device for high-risk percutaneous coronary interventions: a systematic review;Ait Ichou J;Catheter Cardiovasc Interv,2018
4. Progression of aortic regurgitation: the missing link between disease severity and clinical complications;Vanoverschelde JL;J Am Coll Cardiol,2019
5. FDA approves Impella 5.0 and Impella LD extended duration of use to 14 days for cardiogenic shock derived from AMI or cardiomyopathy. FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy | Abiomed.com. (n.d.). Retrieved February 21. (2023). https.//www.abiomed.com/about-us/news-and-media/press-releases/fda-approves-impella-50-and-impella-ld-extended-durati....